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Background: Several studies have reported that the metabolic syndrome (MS) is more common in subjects with HIV
infection than in HIV-negative individuals. HIV infection and the use of Highly Active Antiretroviral Therapy (HAART)
have been shown to predispose HIV-infected persons to MS. In this study, we report the prevalence of MS in Cameroonian
HIV-infected subjects receiving different combinations of HAART as well as HIV patients who have never received
antiretroviral drugs.
Methods: In this cross-sectional study, 173 treated and untreated HIV-infected out-patients (aged 18–70 years)
managed at the Buea and Limbe Regional Hospitals and 50 seronegative individuals (controls) were recruited
after obtaining their consent. Ethical approval for this study was obtained from the National Ethics Committee of
Cameroon. Metabolic syndrome prevalence was examined using the U.S. National Cholesterol Education Program
Adult Treatment Panel III (ATPIII) criteria. Data was analyzed using SPSS® (Statistical Package for the Social Sciences, SPSS
Inc., Chicago, IL, USA) version 16. Statistical significance was set at p < 0.05.
Results and discussion: The prevalence of MS among the HIV patients was 15.6% (27/173) and 8% (4/50) among the
controls and the difference was significant (p = 0.022). MS was more prevalent in HIV-infected patients on HAART than
in ART-naive patients and seronegative individuals. Overall, the prevalence of MS was significantly higher (p = 0.003) in
females (28/153; 18.3%) than in males (3/70; 4.3%). The patients on first-line drugs demonstrated the highest MS
prevalence (15/62; 24.2%) followed by the ART-naïve group of patients (7/61; 11.5%) and the lowest prevalence
was among the patients on protease inhibitors (5/50; 10%). Patients on the drug combination Lamivudine/Stavudine/
Nevirapine had the highest prevalence of MS (50%).
Conclusions: In this study, HAART but not HIV disease plays a significant role in the development of MS. The metabolic
complications as a result of treatment with HAART may predispose HIV patients to developing cardiovascular diseases
and diabetes, in spite of improvements in morbidity and mortality conferred by immune reconstitution as a result of
HAART treatment.
Keywords: Metabolic syndrome, Antiretroviral therapy, HIV, HAART* Correspondence: herberto99@yahoo.com
1Department of Microbiology and Parasitology, University of Buea, P.O. Box
63, Buea, Cameroon
Full list of author information is available at the end of the article
© 2014 Mbunkah et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Mbunkah et al. Diabetology & Metabolic Syndrome 2014, 6:92 Page 2 of 7
http://www.dmsjournal.com/content/6/1/92Background
The use of antiretroviral therapy (ART) especially the
highly active antiretroviral therapy (HAART) has led to
a significant reduction in AIDS related morbidity and
mortality [1]. Although ART has positively modified the
natural history of HIV, long-term toxicity is becoming
recognized. In addition a variety of metabolic abnormal-
ities including dyslipidemia, fat redistribution, high blood
pressure, and insulin resistance have frequently been
associated with ART, particularly when it contains pro-
tease inhibitors [2].
The National Cholesterol Education Program’s Adult
Treatment Panel (ATP) III report identified the metabolic
syndrome (MS) as a multiplex risk factor for cardiovascular
disease and defined it as the occurrence of three or more
of the following abnormalities: hypertriglyceridemia, low
high-density lipoprotein (HDL) cholesterol, hypertension,
abdominal obesity, and high serum glucose [3]. Several
studies have reported that the metabolic syndrome is
more common in subjects with HIV infection than in
HIV-negative individuals [4-6]. The components of meta-
bolic syndrome have been recognized in patients infected
with HIV [7-9].
There is limited information on MS prevalence in
HIV-infected patients receiving HAART worldwide, es-
pecially in the present study site (Cameroon). A Spanish
study reported a prevalence of 17% by the ATP III criteria
[10]. Most patients who come down with MS are at a
greater risk of developing coronary heart disease (CHD)
and diabetes. In this study, we report the prevalence of
MS in HIV-infected subjects receiving different combina-
tions of HAART, HIV patients who have never received
antiretroviral drugs, as well as seronegative individuals
(controls).Research design and methods
This was a cross-sectional study carried out on HIV-
infected out-patients managed at the Buea and Limbe
Regional Hospitals of the South West Region of Cameroon
over a period of 9 months, from November 2010 through
July 2011. These hospitals have the major HIV treatment
centres in the Region. Buea (coordinates: 4°10′0 N 9°14′
0E) is the capital of the South West Region of Cameroon
located on the eastern slopes of Mount Cameroon. Results
of the 2005 census revealed that Buea has a population of
150,000 people. Limbe (coordinates: 4°01′ N 9°13′ E) with
a population of 84,223 is a natural resource coastal city.
The out-patients came from Buea, Limbe and other
surrounding villages (Muea, Tole, Ekona, Mutengene,
Bolifamba, Ombe, Bova and Idenau). The ethical clearance
for this study was one issued by the National Ethics
Committee in Cameroon for an on-going related and
larger study on HIV/AIDS co-infections.All participants were evaluated by trained physicians
after giving their informed consent. Blood samples were
collected into dry vacutainer tubes after a 12-hour
overnight fast and analysed at the Clinical Diagnostic
Laboratory of the University of Buea. A total of 241
participants (aged 18–70 years) were enrolled having
fulfilled the inclusion criteria of the study (HIV positive
people; untreated and those receiving treatment for at
least 1 month who after giving their consent, voluntarily
accepted to take part). Pregnant women and persons who
did not satisfy the inclusion criteria were excluded. Six
participants were on anti-diabetic drugs and twelve on
antihypertensive drugs and were therefore excluded from
the study. Of the 223 qualified participants, 62 were HIV-
infected patients on first-line drug treatment, 50 were
HIV-infected patients on second-line drug treatment, 61
were untreated (ART-naive) HIV-infected patients and a
last group of 50 was made up of HIV negative individuals
(controls). First-line drug treatment was a combination of
2 Nucleotide Reverse Transcriptase Inhibitors (NRTIs) + a
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
while second-line drug treatment was a combination of 2
NRTIs + 2 Protease Inhibitors (P.Is).
A rapid test to screen for the presence of anti-HIV
antibodies was performed using the rapid test kit, Deter-
mine™ HIV-1/2 (Abbot Laboratories, Japan). Confirm-
ation of all results was done using the ImmunoComb® II
HIV-1/2 Bispot kit. Weight, height and waist circumfer-
ence were measured by standard methods and the body
mass index (BMI) calculated. After the patient had rested
for 10 minutes seated in a quiet room, blood pressure
(BP) was measured in the left arm with the elbow flexed
at heart level by a physician using an electronic BP ma-
chine (Airial® Bp2200). Two readings were obtained, and
the average of the systolic and diastolic blood pressure
readings was used. Total serum cholesterol and serum
triglycerides were determined using enzymatic-colorimetric
methods in a Mindray® BA-88 Biochemistry analyzer using
the Cholesterol- HB006 and Triglycerides- HB021 Kits
(Cypress Diagnostics Ltd.) respectively. HDL-cholesterol
was measured using the phosphotungstic precipitation
method with phosphotungstic acid and magnesium ions
(HDL-Cholesterol- HB007 Kit- Cypress Diagnostics Ltd.).
LDL-Cholesterol was calculated using the Friedewald for-
mula [11]. Fasting blood glucose was determined using a
glucometer (Clever Chek® TD-4222) following the manu-
facturer’s instructions. All participants mounted on a body
fat analyzer (Tanita® Bodyfat Analyzer) to obtain a complete
body fat analysis. CD4 counts of the HIV patients were ob-
tained using the Partec® CyFlow Counter (Partec Gmbh)
according to the manufacturer’s instructions.
In the ATP III report of 2001, individuals with three
or more of the following criteria are defined as having
the metabolic syndrome: waist circumference >102 cm
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(1.69 mmol/L); HDL cholesterol <40 mg/dL (1.04 mmol/
L) in men and <50 mg/dL (1.29 mmol/L) in women;
blood pressure ≥130/85 mmHg; and fasting plasma glu-
cose ≥110 mg/dL (6.1 mmol/L).
All statistical calculations were done using the com-
puter program SPSS® (Statistical Package for the Social
Sciences, SPSS Inc., Chicago, IL, USA) version 17. Charts
were produced using Microsoft® Excel 2007. Comparison
of group means of all parameters was performed using the
ANOVA test. Categorical data and the prevalence of MS
in HIV-infected patients were compared using the Pear-
son’s Chi-Square test. A p-value < 0.05 was considered
statistically significant.
Results
A total of 241 participants were enrolled into the study
but 18 were disqualified because they were either on anti-
diabetics or anti-hypertensive drugs. Of the remaining
223, there were 70 (31.4%) males and 153 (68.6%) females.Table 1 Demographic, anthropometric, HIV status and other







Mean Age ± SD 41.1 ± 11.2
Mean CD4 count ± SD (cells/μL) 382 ± 173.2
Mean BMI (kg/m2) ± SD 24.6 ± 4.2
Smokers 2 (3.2)
Alcohol consumers 4 (6.5)
Aerobic exercise 20 (32.3)
Fat mass (Kg): mean (SD) 18.7 (9.7)
Lean Body Mass (Kg): mean (SD) 47.1 (8.9)
Total body water (Kg): mean (SD) 34.3 (6.7)
Clinical staging
Primary 51 (82.3)
Stage 1 11 (17.7)





Obese class 1 5 (8.1)
Obese class 2 1 (1.6)
Obese class 3 0 (0)A majority of the naïve-ART group of patients were in the
primary clinical stage of infection while those on second-
line treatment (protease inhibitor-containing HAART)
group were at clinical stage 1 of infection. This latter
group also had the highest percentage of patients (24%) at
clinical stage 2. The mean CD4 count was highest among
the naïve-ART group of patients, followed by the first-line
treatment group of patients. No participant was on
lipid lowering drugs. The details of the demographic,
anthropometric, HIV status and other characteristics
of the 223 participants are shown in Table 1.
The prevalence of the components of MS was also
evaluated. The highest to the lowest prevalent compo-
nent was low HDL-C (43%), abdominal obesity (36.8%),
hyperglycemia (26.5%), hypertension (24.7%) and hypertri-
glyceridemia (12.1%). The frequency distribution of the
occurrence of these components is shown on Figure 1.
The overall prevalence of MS in this study (Table 2)
was 13.9% with significant differences in the prevalence
among groups (p = 0.022). The prevalence of MS amongcharacteristics of the 223 participants
2nd Line drugs Naïve-ART Controls
(n = 50) (n = 61) (n = 50)
n (%) n (%) n (%)
Positive Positive Negative
31 (62) 44 (72.1) 30 (60)
19 (38) 17 (27.9) 20 (40)
38.7 ± 11.3 36.3 ± 11.8 47.3 ± 13.7
215.1 ± 119 399 ± 212.7 /
23 ± 3.5 23.6 ± 3.8 28.6 ± 6
0 (0) 3 (4.9) 1 (2)
0 (0) 10 (16.4) 4 (8)
7 (14) 18 (29.5) 12 (24)
15.3 (9.2) 17.9 (9.5) 26.7 (17.9)
46.4 (9.6) 45.7 (11.3) 49.3 (9.9)
33.9 (7.0) 34.1 (8.5) 36.0 (7.2)
2 (4) 54 (88.5) /
36 (72) 5 (8.2) /
12 (24) 2 (3.3) /
7 (14) 10 (16.4) 3 (6)
29 (58) 31 (50.8) 14 (28)
10 (20) 17 (27.9) 13 (26)
2 (4) 3 (4.9) 13 (26)
0 (0) 0 (0) 4 (8)
0 (0) 0 (0) 3 (6)
Table 2 Prevalence of metabolic syndrome among groups
Treatment Prevalence P-value
1st Line drug treatment 15/62 (24.2%)
2nd Line drug treatment 5/50 (10%) 0.022*
Naïve 7/61 (11.5%)
Controls 4/50 (8%) χ2 = 9.6
Overall prevalence 31/223 (13.9%)
*Statistically significant.
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(4/50) among the controls. The MS prevalence among
the ART-naive and control groups was compared and
no statistically significant difference (p = 0.542) was found.
A similar comparison was done between all patients on
HAART and the ART-naive group. A statistically signifi-
cant difference (p = 0.020) was found. In the study
population, the prevalence of MS was significantly
higher (p = 0.003) in females (28/153; 18.3%) than in
males (3/70; 4.3%). In those on first-line drug treat-
ment, the prevalence of MS was 29.2% and 7.1% for fe-
males and males respectively. Similarly, when second-line
treatment was considered, the prevalence was 10% for
females and 0% for males.
The relationship between drug combination and MS
was also investigated. MS was most prevalent in patients
receiving the drug combination Lamivudine/Stavudine/
Nevirapine (Table 3). Within the HIV patients, the meta-
bolic syndrome was significantly associated with age, BMI,
waist circumference, fasting blood sugar, triglycerides and
to a lesser extent, HDL cholesterol and sex (Table 4).
The lipid profile differed among the groups. A statisti-
cally significant difference existed in the mean concen-
tration of total cholesterol (TC) between the first-line
and second-line patients (p = 0.027) and also between the
first-line and the naïve (untreated) patients (p = 0.01). The
mean concentration of HDL-C was significantly higher
among the HAART-treated patients than in the untreated
patients (p = 0.021). The mean concentrations of TC and
HDL-C were significantly higher in the controls than in
the treated cases (p = 0.040 and p = 0.032 respectively).
Dyslipidemia was prevalent among the first-line group of
patients (14.5%) followed by the second-line group of
patients (14%) while the naïve-ART patients had a
prevalence of 11%. In the controls, the prevalence wasFigure 1 Prevalence of the components of MS.12%. Overall, the difference in these prevalence rates
was not significant (p = 0.792).
Discussion, conclusions and recommendations
The widespread use of highly active antiretroviral therapy
(HAART) has resulted in a dramatic decrease in the
morbidity and mortality of patients infected with HIV.
Unfortunately, HAART is increasingly associated with
the emergence of adverse metabolic events. There is
evidence of MS following infection with HIV and the
administration of HAART in our study population.
Risk factors of MS such as increased age, BMI, hyper-
tension and hyperglycemia were higher among the HIV
patients diagnosed with MS than in patients without MS.
The MS prevalence among the ART-naive and control
groups was compared and no statistically significant
difference (p = 0.542) was found, indicating that there
isn’t a role for HIV infection on developing the MS. A
similar comparison was done between all patients on
HAART and the ART-naive group. It was found out
that HAART plays a significant role in the development
of MS (p = 0.020). The prevalence of MS was not affected
by HIV disease stage. Patients with MS had a higher mean
CD4 cell count. The type or duration of antiretroviral
therapy was not an independent risk factor for MS. These
Table 3 Prevalence of MS with respect to drug
combination
Drug combination (n) MS (%)
Lamivudine/Zidovudine/Nevirapine† (35) 6 (17.1%)
Lamivudine/Zidovudine/Efavirens† (15) 5 (33.3%)
Lamivudine/Stavudine/Nevirapine† (6) 3 (50%)
Lamivudine/Stavudine/Efavirens† (6) 1 (16.7%)
Lopinavir/Ritonavir/ Lamivudine/Zidovudine ♣ (17) 2 (11.8%)
Lopinavir/Ritonavir/Tenofovir/Lamivudine ♣ (14) 0 (0%)
Lopinavir/Ritonavir/Tenofovir/Emtricitabine ♣ (19) 3 (15.8%)
† = First-line drug combination ♣ = Second-line drug combination n = number.
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sectional study of the risk factors associated with MS
and cardiovascular disease (CVD) among HIV patients
conducted in the US in 2005. It was shown that HIV-
infected patients with MS were older, had a high CD4
cell count and body mass index, compared to patients
without MS and the type or duration of ART was not
an independent risk factor for MS [12]. However, the
study conducted in Barcelona (2005) by Jericŏ and
colleagues revealed that patients with MS presented
with lower CD4 cell counts but higher ages and BMI
than patients without MS.Table 4 Association of age, sex, HIV disease stage, lipodystro
Patients wit
Number (%) 27 (15.6)




Mean BMI in kg/m2 (SD) 25.2 (3.4)
HIV disease stage (%)
Primary 20 (74.1)
Stage 1 3 (11.1)
Stage 2 4 (14.8)
Mean CD4 cell count in cells/μL (SD) 412.4 (173.6)
Mean waist circumference in cm (SD) 94.37 (6.9)
Mean HDL-C in mg/dL (SD) 37.7 (11.9)
Mean FBS in mg/dL (SD) 111.6 (13.0)
Mean triglyceride in mg/dL (SD) 125.5 (73.0)
Antiretroviral therapy exposure
Naïve-ART (%) 7 (25.9)
Never on protease inhibitor (%) 15 (55.6)
Currently protease inhibitor (%) 5 (18.5)
Mean years of HIV infection duration (SD) 3.6 (1.1)
Mean years of HAART duration (SD) 2.4 (0.7)
*Statistically significant.Our study demonstrated that low HDL-C (43%), ab-
dominal obesity (36.8%), hyperglycemia (26.5%), hyper-
tension (24.7%) and hypertriglyceridemia (12.1%) were
the prevalent MS components. In a cross-sectional
study in Barcelona using 710 HIV-infected patients,
Jericŏ et al. [10] demonstrated that hypertriglyceridemia
(95%) was the most frequent trait of MS, followed by low
HDL cholesterol (71.1%), high blood pressure (67.8%), ab-
dominal obesity (47.1%), and high blood glucose levels
(46.3%). Another study with 477 HIV-infected adults
in the US revealed that the most common metabolic
abnormalities were low HDL (54%) and high triglycer-
ides (47%) and the least common was high blood glu-
cose (4%). The prevalence of high blood pressure and
abdominal obesity were 33% and 25% respectively
[13]. In our study, the prevalence of MS components
was dissimilar among the first-line, second-line and
ART-naïve patients. This is contrary to findings in
2007 by Bonfanti et al. [14] where the prevalence of
MS components was similar in treated and never-
treated HIV-infected patients. A larger sample size is
needed to confirm the preliminary findings in the
present study.
The prevalence of MS among the HIV patients was
15.6% and 8% among the uninfected group (controls).phy and HAART with the metabolic syndrome
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that the metabolic syndrome is more common in subjects
with HIV infection than in HIV-negative individuals [4-6].
In a cross-sectional study with 710 HIV-infected patients
in Barcelona, Spain, the prevalence of MS was 17% and
only stavudine and lopinavir/ritonavir were independently
associated with the metabolic syndrome [10]. In this study,
the prevalence of MS was significantly higher in fe-
males than in males. In previous studies, women were
also reported to be more frequently diagnosed with MS
than men [15,16].
MS was more prevalent among patients on first-line
treatment than those on second-line drugs (P.Is). Our
finding contradicts those from other studies reporting
that MS is usually most prevalent among HIV patients
on protease inhibitor-based HAART. In 2007, an inter-
national cross-sectional study of a well-characterized
cohort of 788 HIV-infected adults revealed an 18%
prevalence of the metabolic syndrome and protease in-
hibitor use was associated with a significantly higher
prevalence of MS [15]. Jacobson and colleagues in 2006
demonstrated in their cohort study that lopinavir/ritonavir
users had a higher risk of developing the metabolic syn-
drome [13]. Our study also demonstrated that patients on
the drug combination Lamivudine/Stavudine/Nevirapine
had the highest prevalence of the MS (50%). The drug
stavudine has been noted to be strongly associated with
MS [10,15,17].
In conclusion, MS is more prevalent in HIV-infected pa-
tients on HAART (especially those taking the Lamivudine/
Stavudine/Nevirapine drug combination) than in ART-
naive patients and seronegative individuals. Although
numerous studies have implicated P.Is as an important
risk factor for cardiovascular disease, the use of P.Is
was not found to be an independent risk factor for MS
in the present study. Our study indicates that there isn’t
a role for HIV infection on developing the MS but the
use of HAART plays a significant role in the develop-
ment of MS. The metabolic complications as a result of
treatment with HAART left HIV patients at a risk of
developing CVD and diabetes in spite of improvements
in morbidity and mortality conferred by immune recon-
stitution as a result of HAART treatment. Although the
substantial benefits of combination ART clearly out-
weigh the increase in cardiovascular risk associated
with this therapy, it must be borne in mind that with
progressive aging of the HIV-infected population and
the expected long-term use of combination ART, it is
important to prevent an increased incidence of MS in
this population.
For future studies, we recommend:
➢ The use of larger sample sizes and the recruitment of
patients with longer ART exposure periods.➢ That data should be obtained on pre-existing risk factors
for metabolic syndrome prior to becoming HIV-positive
since this could alter results on MS prevalence.
➢ The inclusion of patients in the late stages of infection.
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